Suppr超能文献

连续低剂量索拉非尼通过改善肿瘤微环境增强了过继性T细胞疗法在小鼠模型中的治疗效果。

Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.

作者信息

Chuang Hui-Yen, Chang Ya-Fang, Liu Ren-Shyan, Hwang Jeng-Jong

机构信息

Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan.

National PET/Cyclotron Center and Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

出版信息

PLoS One. 2014 Oct 15;9(10):e109992. doi: 10.1371/journal.pone.0109992. eCollection 2014.

Abstract

Requirements of large numbers of transferred T cells and various immunosuppressive factors and cells in the tumor microenvironment limit the applications of adoptive T cells therapy (ACT) in clinic. Accumulating evidences show that chemotherapeutic drugs could act as immune supportive instead of immunosuppressive agents when proper dosage is used, and combined with immunotherapy often results in better treatment outcomes than monotherapy. Controversial immunomodulation effects of sorafenib, a multi-kinases inhibitor, at high and low doses have been reported in several types of cancer. However, what is the range of the low-dose sorafenib will influence the host immunity and responses of ACT is still ambiguous. Here we used a well-established E.G7/OT-1 murine model to understand the effects of serial low doses of sorafenib on both tumor microenvironment and transferred CD8+ T cells and the underlying mechanisms. Sorafenib lowered the expressions of immunosuppressive factors, and enhanced functions and migrations of transferred CD8+ T cells through inhibition of STAT3 and other immunosuppressive factors. CD8+ T cells were transduced with granzyme B promoter for driving imaging reporters to visualize the activation and distribution of transferred CD8+ T cells prior to adoptive transfer. Better activations of CD8+ T cells and tumor inhibitions were found in the combinational group compared with CD8+ T cells or sorafenib alone groups. Not only immunosuppressive factors but myeloid derived suppressive cells (MDSCs) and regulatory T cells (Tregs) were decreased in sorafenib-treated group, indicating that augmentation of tumor inhibition and function of CD8+ T cells by serial low doses of sorafenib were via reversing the immunosuppressive microenvironment. These results revealed that the tumor inhibitions of sorafenib not only through eradicating tumor cells but modifying tumor microenvironment, which helps outcomes of ACT significantly.

摘要

肿瘤微环境中大量转移T细胞以及各种免疫抑制因子和细胞的存在限制了过继性T细胞疗法(ACT)在临床上的应用。越来越多的证据表明,当使用适当剂量时,化疗药物可作为免疫支持剂而非免疫抑制剂,并且与免疫疗法联合使用通常比单一疗法产生更好的治疗效果。在几种类型的癌症中,已经报道了多激酶抑制剂索拉非尼在高剂量和低剂量时具有争议性的免疫调节作用。然而,低剂量索拉非尼影响宿主免疫和ACT反应的范围仍不明确。在这里,我们使用成熟的E.G7/OT-1小鼠模型来了解连续低剂量索拉非尼对肿瘤微环境和转移的CD8+ T细胞的影响及其潜在机制。索拉非尼通过抑制STAT3和其他免疫抑制因子,降低了免疫抑制因子的表达,并增强了转移的CD8+ T细胞的功能和迁移能力。在过继性转移之前,用颗粒酶B启动子转导CD8+ T细胞以驱动成像报告基因,从而可视化转移的CD8+ T细胞的激活和分布。与单独的CD8+ T细胞或索拉非尼组相比,联合组中发现CD8+ T细胞的激活更好且肿瘤抑制作用更强。索拉非尼治疗组不仅免疫抑制因子减少,而且髓源性抑制细胞(MDSC)和调节性T细胞(Treg)也减少,这表明连续低剂量索拉非尼增强肿瘤抑制和CD8+ T细胞功能是通过逆转免疫抑制微环境实现的。这些结果表明,索拉非尼对肿瘤的抑制作用不仅通过根除肿瘤细胞,还通过改变肿瘤微环境来实现,这对ACT的治疗效果有显著帮助。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/effb/4198194/edba833edc4c/pone.0109992.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验